Vitiligo
Conditions
Interventions
We will participate in the study 20 patients randomized into 2 study groups: Vitiligo Placebo (1), Vitiligo Fluoxetine (2). Group 2 will receive fluoxetine at the dose of 20 mg daily over a period of
Drug
Sponsors
Universidade Federal de Sergipe
Universidade Federal de Sergipe
Eligibility
Inclusion criteria
Inclusion criteria: Have a diagnosis of segmental or non-segmental vitiligo by dermatologist;be at least 18 years old;have 3 to 50% of the area of the affected body surface
Exclusion criteria
Exclusion criteria: Be carrying out any method of treatment for at least three months, those with any autoimmune disease, patients with more than 50% of the body surface affected, pregnant or lactating women, patients with skin cancer, patients with psychological disorders, patients with photosensitive conditions, vitiligo limited only to the genitals
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increased body surface area affected by vitiligo measured by VES (Vitiligo Extent Score), by photographic record and biomechanical parameters such as melanin and erythema verified by the Courage + Khazaka electronic GmbH-Cutometer® equipment and its specific probes, data collected from the beginning of treatment and at the end of the 4th, 8th and 12th week of treatment used. The increase should be at least 5% of the initial area | — |
Secondary
| Measure | Time frame |
|---|---|
| Increased production of interleukins IL-6, IL, IL-17 measured by laboratory tests like the ELISA method, done before and after intervention, 15% increase when purchased without treatment | — |
Countries
Brazil
Contacts
Public ContactIsabella Almeida
Universidade Federal de Sergipe
Outcome results
None listed